FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Maral Mouradian

Research Profile

Disorders

Parkinson's Disease

Chemicals & Drugs

Living Beings

Mouse
Rats

Procedures

Double-Blind Method

Physiology

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
Kang-Woo Lee; David S Schuster; Patricia K Sonsalla; Jeffry B Stock; Michael Voronkov; Jong-Min Woo; Steven P Braithwaite; Ana Clara Cristovao; Jose R Fernandez; Hilary Grosso; Joo-Young Im; Marla M Jalbut; Eunsung Junn; Yoon-Seong Kim; M Maral Mouradian
Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.
Steven P Braithwaite; Jeffry B Stock; Michael Voronkov; M Maral Mouradian
Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.
Joo-Young Im; Eunsung Junn; Kang-Woo Lee; Jong-Min Woo; M Maral Mouradian
DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Maral Mouradian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kang-Woo Lee; David S Schuster; Patricia K Sonsalla; Jeffry B Stock; Michael Voronkov; Jong-Min Woo; Steven P Braithwaite; Ana Clara Cristovao; Jose R Fernandez; Hilary Grosso; Joo-Young Im; Marla M Jalbut; Eunsung Junn; Yoon-Seong Kim; M Maral Mouradian
Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2013;10(1):143-53.
2012: Steven P Braithwaite; Jeffry B Stock; Michael Voronkov; M Maral Mouradian
Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.
Neurochemistry international 2012;61(6):899-906.
2012: Joo-Young Im; Eunsung Junn; Kang-Woo Lee; Jong-Min Woo; M Maral Mouradian
DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway.
Human molecular genetics 2012;21(13):3013-24.
2012: M Maral Mouradian
MicroRNAs in Parkinson's disease.
Neurobiology of disease 2012;46(2):279-84.
2012: Hilary Grosso; M Maral Mouradian
Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
Pharmacology & therapeutics 2012;133(3):392-410.
2012: Eunsung Junn; M Maral Mouradian
MicroRNAs in neurodegenerative diseases and their therapeutic potential.
Pharmacology & therapeutics 2012;133(2):142-50.
2012: Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Reviews in the neurosciences 2012;23(2):191-8.
2012: Kang-Woo Lee; Patricia K Sonsalla; Xin Zhao; Teresa W Chan; Dwight C German; Hilary Grosso; Hidenori Ichijo; Joo-Young Im; Won Hee Jang; Eunsung Junn; M Maral Mouradian
Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation.
PloS one 2012;7(1):e29935.
2011: Yong Man Kim; Kwang Chul Chung; Won Hee Jang; Eunsung Junn; Yohan Oh; Martha Quezado; M Maral Mouradian
Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation.
Journal of the neurological sciences 2011;307(1-2):157-61.
2011: Kang-Woo Lee; Walter Chen; Eunsung Junn; Joo-Young Im; Hilary Grosso; Patricia K Sonsalla; Xuyan Feng; Neelanjana Ray; Jose R Fernandez; Yang Chao; Eliezer Masliah; Michael Voronkov; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2011;31(19):6963-71.
2011: Yohan Oh; Yong Man Kim; M Maral Mouradian; Kwang Chul Chung
Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation.
Brain research 2011;1381():78-89.
2010: Joo-Young Im; Kang-Woo Lee; Eunsung Junn; M Maral Mouradian
DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex.
Neuroscience research 2010;67(3):203-8.
2010: Xuebing Cao; Toru Yasuda; subramaniam uthayathas; Ray L Watts; M Maral Mouradian; Hideki Mochizuki; Stella M Papa
Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2010;30(21):7335-43.
2010: Eunsung Junn; M Maral Mouradian
MicroRNAs in neurodegenerative disorders.
Cell cycle (Georgetown, Tex.) 2010;9(9):1717-21.
2009: Eunsung Junn; Kang-Woo Lee; Byeong-Seon Jeong; Teresa W Chan; Joo-Young Im; M Maral Mouradian
Repression of alpha-synuclein expression and toxicity by microRNA-7.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(31):13052-7.
2009: Sang-Hyeon Lee; Min-Kyung Jang; Ok-Soo Kim; Ok-Hee Lee; Nam Young Kim; Ki-Hwan Yoo; DONG-GEUN LEE; Young Hwa Shong; M Maral Mouradian
Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone.
The Journal of steroid biochemistry and molecular biology 2009;115(1-2):30-5.
2008: Sang-Hyeon Lee; Min-Kyung Jang; Ok Hee Lee; Ok-Soo Kim; Yong-Man Kim; Shunsuke Yajima; Young-Choon Lee; M Maral Mouradian
Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene.
Molecular and cellular endocrinology 2008;289(1-2):23-8.
2008: Hideki Mochizuki; Toru Yasuda; M Maral Mouradian
Advances in gene therapy for movement disorders.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2008;5(2):260-9.
2008: Myung Yi Ryu; Dong Wan Kim; Kunimasa Arima; M Maral Mouradian; Seung Kim; Gwang Lee
Localization of CKII beta subunits in Lewy bodies of Parkinson's disease.
Journal of the neurological sciences 2008;266(1-2):9-12.
2006: Suhayl Dhib-Jalbut; Douglas L Arnold; Don W Cleveland; Mark Fisher; Robert M Friedlander; M Maral Mouradian; Serge Przedborski; Bruce D Trapp; Tony Wyss-Coray; V Wee Yong
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.
Journal of neuroimmunology 2006;176(1-2):198-215.
2005: William Bara-Jimenez; Francesco Bibbiani; Michael J Morris; Tzvetelina Dimitrova; Abdullah Sherzai; M Maral Mouradian; Thomas N Chase
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2005;20(8):932-6.
2005: Eunsung Junn; Hiroyuki Taniguchi; Byeong-Seon Jeong; Xin Zhao; Hidenori Ichijo; M Maral Mouradian
Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(27):9691-6.
2005: M Maral Mouradian
Should levodopa be infused into the duodenum?
Neurology 2005;64(2):182-3.
2004: William Bara-Jimenez; Tzvetelina Dimitrova; Abdullah Sherzai; Antonella Favit; M Maral Mouradian; Thomas N Chase
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(10):1183-6.
2004: Suhayl Dhib-Jalbut; M Maral Mouradian
Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system.
Expert opinion on biological therapy 2004;4(5):669-75.
2004: Gwang Lee; Mikiei Tanaka; Kiho Park; Sang Seop Lee; Yong Man Kim; Eunsung Junn; Sang-Hyeon Lee; M Maral Mouradian
Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation.
The Journal of biological chemistry 2004;279(8):6834-9.
2004: Tapas K Makar; G David Trisler; MA Eglitis; M Maral Mouradian; Suhayl Dhib-Jalbut
Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice.
Neuroscience letters 2004;356(3):215-9.
2004: Mikiei Tanaka; Yong Man Kim; Gwang Lee; Eunsung Junn; Takeshi Iwatsubo; M Maral Mouradian
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.
The Journal of biological chemistry 2004;279(6):4625-31.
2004: Lawrence I Golbe; M Maral Mouradian
Alpha-synuclein in Parkinson's disease: light from two new angles.
Annals of neurology 2004;55(2):153-6.
2003: Sang Seop Lee; Yong Man Kim; Eunsung Junn; Gwang Lee; K-H Park; Mikiei Tanaka; R D Ronchetti; Martha Quezado; M Maral Mouradian
Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies.
Neurobiology of aging 2003;24(5):687-96.
2003: William Bara-Jimenez; Abdullah Sherzai; Tzvetelina Dimitrova; Antonella Favit; Francesco Bibbiani; M Gillespie; Michael J Morris; M Maral Mouradian; Thomas N Chase
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Neurology 2003;61(3):293-6.
2003: Pierre J Blanchet; Spiros Konitsiotis; Hideki Mochizuki; Ryszard Pluta; Dwaine F Emerich; Thomas N Chase; M Maral Mouradian
Complications of a trophic xenotransplant approach in parkinsonian monkeys.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(4):607-12.
2003: Eunsung Junn; Ruben D Ronchetti; Martha Quezado; Soo-Youl Kim; M Maral Mouradian
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(4):2047-52.
2003: Sang-Hyeon Lee; Yong-Man Kim; Shunsuke Yajima; Jong-Myung Ha; Bae Jin Ha; Ok-Soo Kim; Kanju Ohsawa; M Maral Mouradian
Genomic organization and promoter characterization of the murine dopamine receptor regulating factor (DRRF) gene.
Gene 2003;304():193-9.
2002: Eunsung Junn; Sang Seop Lee; Unsun T Suhr; M Maral Mouradian
Parkin accumulation in aggresomes due to proteasome impairment.
The Journal of biological chemistry 2002;277(49):47870-7.
2002: Gwang Lee; Eunsung Junn; Mikiei Tanaka; Yong Man Kim; M Maral Mouradian
Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival.
Journal of neurochemistry 2002;83(2):346-52.
2002: Tapas K Makar; Susan Wilt; Zhongyun Dong; Paul S Fishman; M Maral Mouradian; Suhayl Dhib-Jalbut
IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2002;22(7):783-91.
2002: Anthone W Dunah; Hyunkyung Jeong; April Griffin; Yong-Man Kim; David G Standaert; Steven M Hersch; M Maral Mouradian; Anne B Young; Naoko Tanese; Dimitri Krainc
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Science (New York, N.Y.) 2002;296(5576):2238-43.
2002: hitoshi okazawa; Tina Rich; Alex Chang; Xi Lin; Masaaki Waragai; Masunori Kajikawa; Yasushi Enokido; Akihiko Komuro; Seishi Kato; Masao Shibata; Hiroshi Hatanaka; M Maral Mouradian; Marius Sudol; Ichiro Kanazawa
Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death.
Neuron 2002;34(5):701-13.
2002: Eunsung Junn; M Maral Mouradian
Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Neuroscience letters 2002;320(3):146-50.
2002: M Maral Mouradian
Recent advances in the genetics and pathogenesis of Parkinson disease.
Neurology 2002;58(2):179-85.
2002: Ursula M D'Souza; Claas-Hinrich Lammers; Cheol Kyu Hwang; Shunsuke Yajima; M Maral Mouradian
Developmental expression of the zinc finger transcription factor DRRF (dopamine receptor regulating factor).
Mechanisms of development 2002;110(1-2):197-201.
2001: K W Park; MA Eglitis; M Maral Mouradian
Protection of nigral neurons by GDNF-engineered marrow cell transplantation.
Neuroscience research 2001;40(4):315-23.
2001: Eunsung Junn; M Maral Mouradian
Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases.
Journal of neurochemistry 2001;78(2):374-83.
2001: Cheol Kyu Hwang; Ursula M D'Souza; Amelia J Eisch; Shunsuke Yajima; Claas-Hinrich Lammers; Y Yang; Sang-Hun Lee; Y M Kim; Eric J Nestler; M Maral Mouradian
Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(13):7558-63.
2001: Leo Verhagen Metman; M Gillespie; C Farmer; Francesco Bibbiani; Spiros Konitsiotis; M Morris; Holly A Shill; William Bara-Jimenez; M Maral Mouradian; Thomas N Chase
Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Clinical neuropharmacology 2001;24(3):163-9.
2001: Ursula M D'Souza; W Wang; D Q Gao; S Kanda; Gwang Lee; Eunsung Junn; Cheol Kyu Hwang; Pedro Jose; M Maral Mouradian
Characterization of the 5' flanking region of the rat D(3) dopamine receptor gene.
Journal of neurochemistry 2001;76(6):1736-44.
2000: Y Yang; Cheol Kyu Hwang; Eunsung Junn; Gwang Lee; M Maral Mouradian
ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene.
The Journal of biological chemistry 2000;275(49):38863-9.
2000: Y Yang; Cheol Kyu Hwang; Ursula M D'Souza; Sang-Hun Lee; Eunsung Junn; M Maral Mouradian
Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcription.
The Journal of biological chemistry 2000;275(27):20734-41.
2000: Masaaki Waragai; Eunsung Junn; M Kajikawa; Shoji Takeuchi; Ichiro Kanazawa; Masao Shibata; M Maral Mouradian; hitoshi okazawa
PQBP-1/Npw38, a nuclear protein binding to the polyglutamine tract, interacts with U5-15kD/dim1p via the carboxyl-terminal domain.
Biochemical and biophysical research communications 2000;273(2):592-5.
2000: S Kanda; JF Bishop; MA Eglitis; Y Yang; M Maral Mouradian
Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.
Neuroscience 2000;97(2):279-84.
1999: Shoji Takeuchi; I Imafuku; Masaaki Waragai; C Roth; Ichiro Kanazawa; R Buettner; M Maral Mouradian; hitoshi okazawa
AP-2beta represses D(1A) dopamine receptor gene transcription in neuro2a cells.
Brain research. Molecular brain research 1999;74(1-2):208-16.
1999: Claas-Hinrich Lammers; Ursula M D'Souza; Zheng-Hong Qin; Sang-Hun Lee; Shunsuke Yajima; M Maral Mouradian
Regulation of striatal dopamine receptors by estrogen.
Synapse (New York, N.Y.) 1999;34(3):222-7.
1999: M Catherine Bennett; JF Bishop; Yan Leng; P B Chock; Thomas N Chase; M Maral Mouradian
Degradation of alpha-synuclein by proteasome.
The Journal of biological chemistry 1999;274(48):33855-8.
1999: Sang-Hun Lee; M Maral Mouradian
Up-regulation of D1A dopamine receptor gene transcription by estrogen.
Molecular and cellular endocrinology 1999;156(1-2):151-7.
1999: Sang-Hun Lee; Shunsuke Yajima; M Maral Mouradian
Neural cell line-specific regulatory DNA cassettes harboring the murine D1A dopamine receptor promoter.
Neuroscience research 1999;34(4):225-34.
1999: Pierre J Blanchet; J Fang; Keith Hyland; Lauren A Arnold; M Maral Mouradian; Thomas N Chase
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.
Neurology 1999;53(1):91-5.
1999: Claas-Hinrich Lammers; Ursula M D'Souza; Zheng-Hong Qin; Sang-Hun Lee; Shunsuke Yajima; M Maral Mouradian
Regulation of striatal dopamine receptors by corticosterone: an in vivo and in vitro study.
Brain research. Molecular brain research 1999;69(2):281-5.
1999: Masaaki Waragai; Claas-Hinrich Lammers; Shoji Takeuchi; I Imafuku; Y Udagawa; Ichiro Kanazawa; M Kawabata; M Maral Mouradian; hitoshi okazawa
PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival.
Human molecular genetics 1999;8(6):977-87.
1999: MA Eglitis; D Dawson; K W Park; M Maral Mouradian
Targeting of marrow-derived astrocytes to the ischemic brain.
Neuroreport 1999;10(6):1289-92.
1999: Amelia J Eisch; Claas-Hinrich Lammers; Shunsuke Yajima; M Maral Mouradian; Eric J Nestler
In vivo regulation of glial cell line-derived neurotrophic factor-inducible transcription factor by kainic acid.
Neuroscience 1999;94(2):629-36.
1998: I Imafuku; Masaaki Waragai; Shoji Takeuchi; Ichiro Kanazawa; M Kawabata; M Maral Mouradian; hitoshi okazawa
Polar amino acid-rich sequences bind to polyglutamine tracts.
Biochemical and biophysical research communications 1998;253(1):16-20.
1998: Pierre J Blanchet; J Fang; M Gillespie; LuAnn A Sabounjian; K W Locke; Richard E Gammans; M Maral Mouradian; Thomas N Chase
Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
Clinical neuropharmacology 1998;21(6):339-43.
1998: Shunsuke Yajima; Sang-Hun Lee; T Minowa; M Maral Mouradian
Sp family transcription factors regulate expression of rat D2 dopamine receptor gene.
DNA and cell biology 1998;17(5):471-9.
1998: L Verhagen Metman; Paolo Del Dotto; Pepijn van den Munckhof; J Fang; M Maral Mouradian; Thomas N Chase
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Neurology 1998;50(5):1323-6.
1997: Shunsuke Yajima; Claas-Hinrich Lammers; Sang-Hun Lee; Y Hara; K Mizuno; M Maral Mouradian
Cloning and characterization of murine glial cell-derived neurotrophic factor inducible transcription factor (MGIF).
The Journal of neuroscience : the official journal of the Society for Neuroscience 1997;17(22):8657-66.
1997: Sang-Hun Lee; W Wang; Shunsuke Yajima; Pedro Jose; M Maral Mouradian
Tissue-specific promoter usage in the D1A dopamine receptor gene in brain and kidney.
DNA and cell biology 1997;16(11):1267-75.
1997: JF Bishop; G Joshi; G P Mueller; M Maral Mouradian
Localization of putative calcium-responsive regions in the rat BDNF gene.
Brain research. Molecular brain research 1997;50(1-2):154-64.
1997: Leo Verhagen Metman; Pepijn van den Munckhof; A A Klaassen; P Blanchet; M Maral Mouradian; Thomas N Chase
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
Neurology 1997;49(3):711-3.
1997: Pierre J Blanchet; S M Papa; Leo Verhagen Metman; M Maral Mouradian; Thomas N Chase
Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
Neuroscience and biobehavioral reviews 1997;21(4):447-53.
1997: M Maral Mouradian; Thomas N Chase
Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
Experimental neurology 1997;144(1):51-7.
1997: L Verhagen Metman; E R Locatelli; D Bravi; M Maral Mouradian; Thomas N Chase
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Neurology 1997;48(2):369-72.
1997: JM Chernak; P W Hoffman; T Minowa; M Maral Mouradian; George S Roth
Interaction of nuclear factors from young and old rat brain regions with regulatory sequences of the D2 dopamine receptor gene promoter.
Brain research. Molecular brain research 1997;44(1):113-24.
1996: hitoshi okazawa; I Imafuku; M T Minowa; Ichiro Kanazawa; H Hamada; M Maral Mouradian
Regulation of striatal D1A dopamine receptor gene transcription by Brn-4.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(21):11933-8.
1996: Sang-Hun Lee; M T Minowa; M Maral Mouradian
Two distinct promoters drive transcription of the human D1A dopamine receptor gene.
The Journal of biological chemistry 1996;271(41):25292-9.
1996: Pierre J Blanchet; Leo Verhagen Metman; M Maral Mouradian; Thomas N Chase
Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(5):580-1.
1996: M T Minowa; Sang-Hun Lee; M Maral Mouradian
Autoregulation of the human D1A dopamine receptor gene by cAMP.
DNA and cell biology 1996;15(9):759-67.
1996: W Wang; K H Hahn; J F Bishop; D Q Gao; Pedro Jose; M Maral Mouradian
Up-regulation of D3 dopamine receptor mRNA by neuroleptics.
Synapse (New York, N.Y.) 1996;23(3):232-5.
1996: I Imafuku; M Kamei; Ichiro Kanazawa; M Maral Mouradian; hitoshi okazawa
POU transcription factors differentially regulate the D1A dopamine receptor gene in cultured cells.
Biochemical and biophysical research communications 1996;222(3):736-41.
1996: Leo Verhagen Metman; Pierre J Blanchet; D de Jong; M Maral Mouradian; Thomas N Chase
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(3):257-60.
1996: Thomas N Chase; T M Engber; M Maral Mouradian
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
Advances in neurology 1996;69():497-501.
1994: J F Bishop; G P Mueller; M Maral Mouradian
Alternate 5' exons in the rat brain-derived neurotrophic factor gene: differential patterns of expression across brain regions.
Brain research. Molecular brain research 1994;26(1-2):225-32.
1994: Leo Verhagen Metman; V H Sethy; J R Roberts; D Bravi; J I Hoff; M Maral Mouradian; Thomas N Chase
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1994;9(5):577-81.
1994: I Litvan; R Blesa; K Clark; Paolo Nichelli; J R Atack; M Maral Mouradian; Jordan Grafman; Thomas N Chase
Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
Annals of neurology 1994;36(1):55-61.
1994: D Bravi; M Maral Mouradian; J W Roberts; T L Davis; Y H Sohn; Thomas N Chase
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Annals of neurology 1994;36(1):27-31.
1994: Leo Verhagen Metman; J Hoff; M Maral Mouradian; Thomas N Chase
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Movement disorders : official journal of the Movement Disorder Society 1994;9(4):463-5.
1994: Thomas N Chase; T M Engber; M Maral Mouradian
Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
Neurology 1994;44(7 Suppl 6):S15-8.
1994: J Blin; Monford Piercey; M E Giuffra; M Maral Mouradian; Thomas N Chase
Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.
Journal of the neurological sciences 1994;123(1-2):44-51.
1994: T Minowa; M T Minowa; M Maral Mouradian
Negative modulator of the rat D2 dopamine receptor gene.
The Journal of biological chemistry 1994;269(15):11656-62.
1994: D Q Gao; L M Canessa; M Maral Mouradian; Pedro Jose
Expression of the D2 subfamily of dopamine receptor genes in kidney.
The American journal of physiology 1994;266(4 Pt 2):F646-50.
1994: Y H Sohn; Leo Verhagen Metman; D Bravi; I Linfante; A Aotsuka; M Maral Mouradian; Thomas N Chase
Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Neurology 1994;44(4):755-7.
1994: J Blin; C A Ray; Monford Piercey; J J Bartko; M Maral Mouradian; Thomas N Chase
Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.
Brain research 1994;635(1-2):196-202.
1994: C Randolph; J W Roberts; M C Tierney; D Bravi; M Maral Mouradian; Thomas N Chase
D-cycloserine treatment of Alzheimer disease.
Alzheimer disease and associated disorders 1994;8(3):198-205.
1993: Thomas N Chase; M Maral Mouradian; T M Engber
Motor response complications and the function of striatal efferent systems.
Neurology 1993;43(12 Suppl 6):S23-7.
1993: J W Roberts; G Cora-Locatelli; D Bravi; M A Amantea; M Maral Mouradian; Thomas N Chase
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Neurology 1993;43(12):2685-8.
1993: M T Minowa; T Minowa; M Maral Mouradian
Activator region analysis of the human D1A dopamine receptor gene.
The Journal of biological chemistry 1993;268(31):23544-51.
1993: J F Bishop; M Maral Mouradian
Characterization of a corticotropin releasing hormone responsive region in the murine proopiomelanocortin gene.
Molecular and cellular endocrinology 1993;97(1-2):165-71.
1993: D Bravi; M Maral Mouradian; J W Roberts; T L Davis; Thomas N Chase
End-of-dose dystonia in Parkinson's disease.
Neurology 1993;43(10):2130-1.
1993: M Giuffra; M Maral Mouradian; T L Davis; J Ownby; Thomas N Chase
Dynorphin agonist therapy of Parkinson's disease.
Clinical neuropharmacology 1993;16(5):444-7.
1993: Robin A Felder; S Kinoshita; K Ohbu; M Maral Mouradian; David R Sibley; F J Monsma; T Minowa; M T Minowa; L M Canessa; Pedro Jose
Organ specificity of the dopamine1 receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats.
The American journal of physiology 1993;264(4 Pt 2):R726-32.
1993: D Bravi; T L Davis; M Maral Mouradian; Thomas N Chase
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Movement disorders : official journal of the Movement Disorder Society 1993;8(2):195-7.
1993: I Yamaguchi; Pedro Jose; M Maral Mouradian; L M Canessa; F J Monsma; David R Sibley; K Takeyasu; Robin A Felder
Expression of dopamine D1A receptor gene in proximal tubule of rat kidneys.
The American journal of physiology 1993;264(2 Pt 2):F280-5.
1993: A Horiuchi; K Takeyasu; M Maral Mouradian; Pedro Jose; Robin A Felder
D1A dopamine receptor stimulation inhibits Na+/K(+)-ATPase activity through protein kinase A.
Molecular pharmacology 1993;43(2):281-5.
1993: M Maral Mouradian; M T Minowa; T Minowa
Promoter structure of the human gene coding for the D1A dopamine receptor.
Advances in neurology 1993;60():343-5.
1993: Thomas N Chase; T M Engber; M Maral Mouradian
Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
Advances in neurology 1993;60():181-5.
1993: M E Giuffra; V H Sethy; T L Davis; M Maral Mouradian; Thomas N Chase
Milacemide therapy for Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8(1):47-50.
1992: fabio baronti; M Maral Mouradian; T L Davis; M Giuffra; G Brughitta; Katherine Conant; Thomas N Chase
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Annals of neurology 1992;32(6):776-81.
1992: T Minowa; M T Minowa; M Maral Mouradian
Analysis of the promoter region of the rat D2 dopamine receptor gene.
Biochemistry 1992;31(36):8389-96.
1992: fabio baronti; M Maral Mouradian; Katherine Conant; M Giuffra; G Brughitta; Thomas N Chase
Partial dopamine agonist therapy of levodopa-induced dyskinesias.
Neurology 1992;42(6):1241-3.
1992: M T Minowa; T Minowa; F J Monsma; David R Sibley; M Maral Mouradian
Characterization of the 5' flanking region of the human D1A dopamine receptor gene.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(7):3045-9.
1992: M E Giuffra; M Maral Mouradian; Thomas N Chase
Glutamatergic therapy of Huntington's chorea.
Clinical neuropharmacology 1992;15(2):148-51.
1992: fabio baronti; T L Davis; R C Boldry; M Maral Mouradian; Thomas N Chase
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Neurology 1992;42(3 Pt 1):541-4.
1992: I J Heuser; fabio baronti; C A Marin; N Ma; G R Merriam; Thomas N Chase; M Maral Mouradian
Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies.
Neurobiology of aging 1992;13(2):255-60.
1991: fabio baronti; Stefano Ruggieri; M Maral Mouradian; A Bonamartini; P Bocciarelli; Maria Francesca De Pandis; Thomas N Chase; A Agnoli
[Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
Rivista di neurologia 1991;61(6):210-4.
1991: I J Heuser; Thomas N Chase; M Maral Mouradian
The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease.
Biological psychiatry 1991;30(9):943-52.
1991: M Maral Mouradian; J Blin; M Giuffra; I J Heuser; fabio baronti; J Ownby; Thomas N Chase
Somatostatin replacement therapy for Alzheimer dementia.
Annals of neurology 1991;30(4):610-3.
1991: fabio baronti; Katherine Conant; M Giuffra; T L Davis; G Brughitta; Michael Iadarola; W H Berrettini; Thomas N Chase; M Maral Mouradian
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Brain research 1991;560(1-2):92-6.
1991: T L Davis; G Brughitta; fabio baronti; M Maral Mouradian
Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
Neurology 1991;41(5):630-3.
1991: M Maral Mouradian; I J Heuser; fabio baronti; M Giuffra; Katherine Conant; T L Davis; Thomas N Chase
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(5):401-5.
1990: M Maral Mouradian; I J Heuser; fabio baronti; Thomas N Chase
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Annals of neurology 1990;27(1):18-23.
1990: Thomas N Chase; Giovanni Fabbrini; Jorge L Juncos; M Maral Mouradian
Motor response complications with chronic levodopa therapy.
Advances in neurology 1990;53():377-81.
1989: Thomas N Chase; fabio baronti; Giovanni Fabbrini; I J Heuser; Jorge L Juncos; M Maral Mouradian
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Neurology 1989;39(11 Suppl 2):7-10; discussion 19.
1989: I Litvan; C Gomez; J R Atack; M Gillespie; A M Kask; M Maral Mouradian; Thomas N Chase
Physostigmine treatment of progressive supranuclear palsy.
Annals of neurology 1989;26(3):404-7.
1989: M Maral Mouradian; I J Heuser; fabio baronti; Giovanni Fabbrini; Jorge L Juncos; Thomas N Chase
Pathogenesis of dyskinesias in Parkinson's disease.
Annals of neurology 1989;25(5):523-6.
1989: A Braun; M Maral Mouradian; E Mohr; Giovanni Fabbrini; Thomas N Chase
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
Journal of neurology, neurosurgery, and psychiatry 1989;52(5):631-5.
1988: Thomas N Chase; Jorge L Juncos; Giovanni Fabbrini; M Maral Mouradian
Motor response complications in advanced Parkinson's disease.
Functional neurology 1988;3(4):429-36.
1988: M Maral Mouradian; Jorge L Juncos; Giovanni Fabbrini; J Schlegel; J J Bartko; Thomas N Chase
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Annals of neurology 1988;24(3):372-8.
1988: Giovanni Fabbrini; M Maral Mouradian; Jorge L Juncos; J Schlegel; E Mohr; Thomas N Chase
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
Annals of neurology 1988;24(3):366-71.
1988: M Maral Mouradian; Thomas N Chase
Central mechanisms and levodopa response fluctuations in Parkinson's disease.
Clinical neuropharmacology 1988;11(4):378-85.
1988: M Maral Mouradian; E Mohr; J A Williams; Thomas N Chase
No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
Neurology 1988;38(4):606-8.
1988: Giovanni Fabbrini; A Braun; M Maral Mouradian; Carol A Tamminga; Thomas N Chase
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
Journal of neural transmission 1988;71(3):159-63.
1987: Jorge L Juncos; Giovanni Fabbrini; M Maral Mouradian; C Serrati; Thomas N Chase
Dietary influences on the antiparkinsonian response to levodopa.
Archives of neurology 1987;44(10):1003-5.
1987: M Maral Mouradian; Jorge L Juncos; Giovanni Fabbrini; Thomas N Chase
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
Annals of neurology 1987;22(4):475-9.
1987: M Maral Mouradian; Jorge L Juncos; C Serrati; Giovanni Fabbrini; S Palmeri; Thomas N Chase
Exercise and the antiparkinsonian response to levodopa.
Clinical neuropharmacology 1987;10(4):351-5.
1987: Jorge L Juncos; M Maral Mouradian; Giovanni Fabbrini; C Serrati; Thomas N Chase
Levodopa methyl ester treatment of Parkinson's disease.
Neurology 1987;37(7):1242-5.
1987: Giovanni Fabbrini; Jorge L Juncos; M Maral Mouradian; C Serrati; Thomas N Chase
3-O-methyldopa and motor fluctuations in Parkinson's disease.
Neurology 1987;37(5):856-9.
1987: Giovanni Fabbrini; Jorge L Juncos; M Maral Mouradian; C Serrati; Thomas N Chase
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Annals of neurology 1987;21(4):370-6.
1987: Jorge L Juncos; Giovanni Fabbrini; M Maral Mouradian; C Serrati; A M Kask; Thomas N Chase
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1987;50(2):194-8.
1987: A Braun; Giovanni Fabbrini; M Maral Mouradian; C Serrati; P Barone; Thomas N Chase
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
Journal of neural transmission 1987;68(1-2):41-50.